Saturday 17 October 2026
Export SYRE’s income statement to Excel — free account
Spyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022. In the quarter to June 2026, EPS grew 26.5% and free cash flow fell 50.1%, each against the same quarter a year earlier.
79.90
0.20
−0.25%
Follow SYRE
Spyre Therapeutics, Inc. (SYRE) P/E ratio
Spyre Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| 19 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SYRE Spyre Therapeutics, Inc. | n/m |
| ABVX Abivax SA Sponsored ADR compare | n/m |
| PRAX Praxis Precision Medicines, Inc. compare | n/m |
| IOVA Iovance Biotherapeutics, Inc. compare | n/m |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | n/m |
| AXSM Axsome Therapeutics, Inc. compare | n/m |
| IONS Ionis Pharmaceuticals, Inc. compare | n/m |
| TGTX TG Therapeutics, Inc. compare | 17.8× |
| PTGX Protagonist Therapeutics, Inc. compare | 106× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)